Improving the value of molecular testing:current status and opportunities in colorectal cancer precision medicine

作     者：Haiyun Li Linwei Guo Chenchen Wang Xin Hu Ye Xu Haiyun Li;Linwei Guo;Chenchen Wang;Xin Hu;Ye Xu

作者机构：Department of Colorectal SurgeryFudan University Shanghai Cancer CenterShanghai 200032China Department of OncologyShanghai Medical CollegeFudan UniversityShanghai 200032China Department of Gastrointestinal Medical OncologyFudan University Shanghai Cancer CenterShanghai 200032China Precision Cancer Medical Center Affiliated with Fudan University Shanghai Cancer CenterShanghai 201315China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2024年第21卷第1期

页      面：21-28页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：the Ministry of Science and Technology of China(Grant No.2018YFE0201604) the National Natural Science Foundation of China(Grant No.81872137 and 82072917) the Science and Technology Commission of Shanghai Municipality(Grant No.20DZ1100100)。 

主　　题：cancer chemotherapy colorectal 

摘      要：Colorectal cancer(CRC)is the second leading cause of cancer-related deaths worldwide1.Surgical radical resection with adjuvant chemotherapy remains the primary treatment choice for CRC,but the 5-year postoperative survival rate is only approximately 60%,and approximately one-third of patients with CRC experience recurrence within 2 years of surgery2.Fortunately,the transformation of high-throughput sequencing has accelerated the development of precision medicine.For example,KRAS mutations indicate resistance to anti-epidermal growth factor receptor(EGFR)-targeted therapies in CRC3.Furthermore,molecular-guided individualized therapy has brought new promise in major clinical areas and challenges,such as novel biomarkers predicting sensitivity and resistance to immunotherapy for microsatellite stable(MSS)CRC.